Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 14, 2025 16:01 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

60 Degrees to seek FDA MUMS designation for tafenoquine in canine babesiosis, supported by 3 studies showing efficacy and safety in treating babesiosis.
April 03, 2024 07:58 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis

60 Degrees Pharma (Nasdaq: SXTP) will sponsor a study using tafenoquine, an FDA-approved malaria drug, to treat canine babesiosis, a tick-borne disease.